Acknowledgements
MAY
We thank the patients and their families for helping us reimagine brain health. We thank the clinical trial investigators and their staff at sites throughout the country. We thank Manny Garcia, MD, for assistance with early drafts of this manuscript. Medical writing support was provided by Gregory Suess, PhD, and Johnson Ying, PhD, of AlphaBioCom, LLC, a Red Nucleus company, and funded by Sage Therapeutics, Inc., and Biogen, Inc. Acknowledgment of past congress presentations: Portions of these data were previously presented at the American Society of Clinical Psychopharmacology (ASCP) 2022 Annual Meeting in Scottsdale, Arizona, May 31–June 03, 2022.